Haemodialysis vascular access is a ‘lifeline’ for almost 2 million patients worldwide; yet given the substantial problems associated with access dysfunction, vascular access is also the Achilles heel of haemodialysis. Recent data suggest that use of novel bioengineered human acellular vessels for haemodialysis access might help to overcome these problems.
Refers to: Lawson, J. H. et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet 387, 2026-2034 (2016).